The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Chaitra Ujjani, 1 Anthony Mato, 2 Brian T Hill, 3 John N Allan, 4 Erick Lansigan, 5 Ryan Jacobs, 6 Hande Tuncer, 7 John Pagel, 8 Danielle Brander, 9 Bruce Cheson, 10 Paul Barr, 11 Lindsey E Roeker, 2 Jeffrey Pu, 12 Nirav N Shah, 13 Andre Goy, 14 Stephen J Schuster, 15 Nicole Lamanna, 16 Alison Sehga...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
cll
ibrutinib
elderly
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/55e83f385ab34228a9f4be53365dc63d

Ejemplares similares